Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Zoster-048
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Jun 2017 According to a GlaxoSmithKline media release, company is sharing these data on safety, local and systemic reactions, and immunogenicity with the US Food and Drug Administration (FDA) and expects that the data could eventually inform a policymaking decision regarding revaccination for protection against shingles with Shingrix.
    • 21 Jun 2017 Results from this study published in a GlaxoSmithKline Media Release.
    • 21 Jun 2017 According to a GlaxoSmithKline media release, data from this study will be presented at the US Centers for Disease Control and Preventions Advisory Committee on Immunization Practices (ACIP) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top